Werewolf Therapeutics' revenue performance is uncertain, and...
Werewolf Therapeutics' revenue performance is uncertain, and it's P/S ratio is low compared to the biotech industry due to potential shrink in revenues. Its low P/S ratio is justified given other companies' revenue growth forecasts, indicating no significant share price rise.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000310014ba72a17b.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment